Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders

SLAS Technology

Volumn 22, Issue 3, 2017, Pages 254-275

  Weiss, Andrea ^a   Nowak Sliwinska, Patrycja ^b  

^a EPFL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

drug mixture optimization; drug drug interactions; feedback system control; response surface; synergistic drug combinations; top down approach

Indexed keywords

BIOINFORMATICS; COMPLEX NETWORKS; DIAGNOSIS; DISEASES; DRUG INTERACTIONS; ONCOLOGY; OPTIMIZATION;

DOSE LIMITING TOXICITY; DRUG COMBINATIONS; FEEDBACK SYSTEMS; HEURISTIC OPTIMIZATION TECHNIQUE; OPTIMIZATION PROBLEMS; OPTIMIZATION TECHNIQUES; RESPONSE SURFACE; TOP DOWN APPROACHES;

DRUG DOSAGE;

ACCURACY; ALGORITHM; CANCER THERAPY; DRUG INTERACTION; ENZYME KINETICS; FEEDBACK SYSTEM; GENE MUTATION; GENOTYPE; HUMAN; MULTIDRUG RESISTANCE; PHENOTYPE; RESPONSE SURFACE METHOD; REVIEW; SCREENING TEST; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; COMBINATION DRUG THERAPY; DRUG SCREENING; MASS SCREENING; NEOPLASM; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; HUMANS; MASS SCREENING; NEOPLASMS;

EID: 85019380720     PISSN: 24726303     EISSN: 24726311     Source Type: Journal    
DOI: 10.1177/2472630316682338     Document Type: Review

References (120)

1. De Francesco R, Migliaccio G. Challenges and Successes in Developing New Therapies for Hepatitis C. Nature 2005, 436 (7053), 953–960.
2. Lehar J., Krueger A. S., Avery W.. Synergistic Drug Combinations Tend to Improve Therapeutically Relevant Selectivity. Nat. Biotechnol. 2009, 27 (7), 659–666.
3. Lindsay M. A., Target Discovery. Nat. Rev. Drug Discov. 2003, 2 (10), 831–838.
4. Baselga J., Targeting Tyrosine Kinases in Cancer: The Second Wave. Science 2006, 312 (5777), 1175–1178.
5. Gotink K. J., Verheul H. M., Anti-Angiogenic Tyrosine Kinase Inhibitors: What Is Their Mechanism of Action? Angiogenesis 2010, 13 (1), 1–14.
6. Smith I., Procter M., Gelber R. D.. 2-Year Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer: A Randomised Controlled Trial. Lancet 2007, 369 (9555), 29–36.
7. Druker B. J., Guilhot F., O’Brien S. G.. Five-Year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N. Engl. J. Med. 2006, 355 (23), 2408–2417.
8. Lynch T. J., Bell D. W., Sordella R.. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2004, 350 (21), 2129–2139.
9. Fitzgerald J. B., Schoeberl B., Nielsen U. B.. Systems Biology and Combination Therapy in the Quest for Clinical Efficacy. Nat. Chem. Biol. 2006, 2 (9), 458–466.
10. Misale S., Bozic I., Tong J.. Vertical Suppression of the EGFR Pathway Prevents Onset of Resistance in Colorectal Cancers. Nat. Commun. 2015, 6, 8305.
11. Bozic I., Reiter J. G., Allen B.. Evolutionary Dynamics of Cancer in Response to Targeted Combination Therapy. eLife 2013, 2, e00747.
12. Schmitt M. W., Loeb L. A., Salk J. J., The Influence of Subclonal Resistance Mutations on Targeted Cancer Therapy. Nat. Rev. Clin. Oncol. 2016, 13 (6), 335–347.
13. Xie L., Xie L., Kinnings S. L.. Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs. Ann. Rev. Pharmacol. Tox. 2012, 52, 361–379.
14. Griffioen A. W., Weiss A., Berndsen R. H.. The Emerging Quest for the Optimal Angiostatic Combination Therapy. Biochem. Soc. Trans. 2014, 42(6), 1608–1615.
15. Freireich E. J., Karon M., Frei E., III. Quadruple Combination Therapy (VAMP) for Acute Lymphocytic Leukemia of Childhood. Proc. Am. Assoc. Cancer Res. 1964, 5, 20.
16. Decker S., Sausville E. A., Preclinical Modeling of Combination Treatments: Fantasy or Requirement? Ann. N.Y. Acad. Sci. 2005, 1059, 61–69.
17. Tol J., Koopman M., Cats A.. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. N. Engl. J. Med. 2009, 360 (6), 563–572.
18. Negrier S., Gravis G., Perol D.. Temsirolimus and Bevacizumab, or Sunitinib, or Interferon Alfa and Bevacizumab for Patients with Advanced Renal Cell Carcinoma (TORAVA): A Randomised Phase 2 Trial. Lancet Oncol. 2011, 12 (7), 673–680.
19. Azad N. S., Posadas E. M., Kwitkowski V. E.. Combination Targeted Therapy with Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity. J. Clin. Oncol. 2008, 26 (22), 3709–3714.
20. Flaherty K. T., Manola J. B., Pins M.. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J. Clin. Oncol. 2015, 33 (21), 2384–2391.
21. Ross N. T., Wilson C. J., In Vitro Clinical Trials: The Future of Cell-Based Profiling. Front. Pharmacol. 2014, 5, 121.
22. Beckman R. A., Schemmann G. S., Yeang C. H., Impact of Genetic Dynamics and Single-Cell Heterogeneity on Development of Nonstandard Personalized Medicine Strategies for Cancer. Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (36), 14586–14591.
23. Eichler E. E., Flint J., Gibson G.. Missing Heritability and Strategies for Finding the Underlying Causes of Complex Disease. Nat. Rev. Genet. 2010, 11 (6), 446–450.
24. Manolio T. A., Collins F. S., Cox N. J.. Finding the Missing Heritability of Complex Diseases. Nature 2009, 461 (7265), 747–753.
25. Hawgood S., Hook-Barnard I. G., O’Brien T. C.. Precision Medicine: Beyond the Inflection Point. Sci. Transl. Med. 2015, 7 (300), 300ps17.
26. Dancey J. E., Chen H. X., Strategies for Optimizing Combinations of Molecularly Targeted Anticancer Agents. Nat. Rev. Drug Discov. 2006, 5 (8), 649–659.
27. Feala J. D., Cortes J., Duxbury P. M.. Systems Approaches and Algorithms for Discovery of Combinatorial Therapies. WIRE Syst. Biol. Med. 2010, 2 (2), 181–193.
28. Cheng A. A., Ding H., Lu T. K., Enhanced Killing of Antibiotic-Resistant Bacteria Enabled by Massively Parallel Combinatorial Genetics. Proc. Natl. Acad. Sci. U.S.A. 2014, 111 (34), 12462–12467.
29. Geva-Zatorsky N., Dekel E., Cohen A. A.. Protein Dynamics in Drug Combinations: A Linear Superposition of Individual-Drug Responses. Cell 2010, 140 (5), 643–651.
30. Wood K., Nishida S., Sontag E. D.. Mechanism-Independent Method for Predicting Response to Multidrug Combinations in Bacteria. Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (30), 12254–12259.
31. Box G. E. P., Wilson K. G., On the Experimental Attainment of Optimum Conditions. 1951, 13, 1–45.
32. Bas D., Boyaci I. H., Modeling and Optimization I: Usability of Response Surface Methodology. J. Food Eng. 2007, 78 (3), 836–845.
33. Carter W. H., Jr. Stablein D. M., Wampler G. L., An Improved Method for Analyzing Survival Data from Combination Chemotherapy Experiments. Cancer Res. 1979, 39 (9), 3446–3453.
34. Carter W. H., Jr. Wampler G. L., Review of the Application of Response Surface Methodology in the Combination Therapy of Cancer. Cancer Treat. Rep. 1986, 70 (1), 133–140.
35. Carter W. H., Jr. Wampler G. L., Stablein D. M.. Drug Activity and Therapeutic Synergism in Cancer Treatment. Cancer Res. 1982, 42 (8), 2963–2971.
36. Stablein D. M., Carter W. H., Jr. Wampler G. L., Confidence Regions for Constrained Optima in Response-Surface Experiments. Biometrics 1983, 39 (3), 759–763.
37. Wampler G. L., Carter W. H., Jr. Glazier R. L.. In Dose-Response Relationships of Adriamycin (ADR) Cyclophosphamide (CTX) in Treatment of Squamous Cell Carcinoma of the Lung—A Pilot Study; ORIC American Association for Cancer Research and ASCO: Philadelphia, 1979; p 401.
38. Weiss A., Berndsen R. H., Ding X.. A Streamlined Search Technology for Identification of Synergistic Drug Combinations. Sci. Rep. 2015, 5, 14508.
39. Gennings C., Carter W. H., Jr. Carchman R. A.. A Unifying Concept for Assessing Toxicological Interactions: Changes in Slope. Toxicol. Sci. 2005, 88 (2), 287–297.
40. Wu C. F. J., Hamada M. S., Experiments: Planning, Analysis, and Optimization; Wiley: New York, 2009; 2nd ed.
41. Pritchard J. R., Bruno P. M., Gilbert L. A.. Defining Principles of Combination Drug Mechanisms of Action. Proc. Natl. Acad. Sci. U.S.A. 2013, 110 (2), E170–E179.
42. Chen H. C., Gau V., Zhang D. D.. Statistical Metamodeling for Revealing Synergistic Antimicrobial Interactions. PLoS One 2010, 5 (11), e15472.
43. Xu H., Jaynes J., Ding X., Combining Two-Level and Three-Level Orthogonal Arrays for Factor Screening and Response Surface Exploration. Stat. Sin. 2014, 24, 269–289.
44. Silva A., Lee B. Y., Clemens D. L.. Output-Driven Feedback System Control Platform Optimizes Combinatorial Therapy of Tuberculosis Using a Macrophage Cell Culture Model. Proc. Natl. Acad. Sci. U.S.A. 2016, 113 (15), E2172–E2179.
45. Wang H., Lee D. K., Chen K. Y.. Mechanism-Independent Optimization of Combinatorial Nanodiamond and Unmodified Drug Delivery Using a Phenotypically Driven Platform Technology. ACS Nano 2015, 9 (3), 3332–3344.
46. Lombardi F., Golla K., Fitzpatrick D. J.. Discovering Anti-Platelet Drug Combinations with an Integrated Model of Activator-Inhibitor Relationships, Activator-Activator Synergies and Inhibitor-Inhibitor Synergies. PLoS Comput. Biol. 2015, 11 (4), e1004119.
47. Pivetta T., Isaia F., Trudu F.. Development and Validation of a General Approach to Predict and Quantify the Synergism of Anti-Cancer Drugs Using Experimental Design and Artificial Neural Networks. Talanta 2013, 115, 84–93.
48. Van der Borght K., Van Craenenbroeck E., Lecocq P.. Cross-Validated Stepwise Regression for Identification of Novel Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Associated Mutations. BMC Bioinformatics 2011, 12, 386.
49. Minto C. F., Schnider T. W., Short T. G.. Response Surface Model for Anesthetic Drug Interactions. Anesthesiology 2000, 92 (6), 1603–1616.
50. Ning S., Xu H., Al-Shyoukh I.. An Application of a Hill-Based Response Surface Model for a Drug Combination Experiment on Lung Cancer. Stat. Med. 2014, 33 (24), 4227–4236.
51. Chou T. C., Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 2006, 58 (3), 621–681.
52. Wood K. B., Wood K. C., Nishida S.. Uncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells. Cell Rep. 2014, 6 (6), 1073–1084.
53. Wood K. B., Cluzel P., Trade-Offs between Drug Toxicity and Benefit in the Multi-Antibiotic Resistance System Underlie Optimal Growth of E. coli. BMC Syst. Biol 2012, 6, 48.
54. Zarrinpar A., Lee D. K., Silva A.. Individualizing Liver Transplant Immunosuppression Using a Phenotypic Personalized Medicine Platform. Sci. Transl. Med. 2016, 8 (333), 333ra49.
55. Takayama K., Fujikawa M., Obata Y.. Neural Network Based Optimization of Drug Formulations. Adv. Drug Deliv. Rev. 2003, 55 (9), 1217–1231.
56. Cheng F., Zhao Z., Machine Learning-Based Prediction of Drug-Drug Interactions by Integrating Drug Phenotypic, Therapeutic, Chemical, and Genomic Properties. J. Am. Med. Inform. Assoc. 2014, 21 (e2), e278–e286.
57. Vilar S., Harpaz R., Uriarte E.. Drug-Drug Interaction through Molecular Structure Similarity Analysis. J. Am. Med. Inform Assoc. 2012, 19 (6), 1066–1074.
58. Burbidge R., Trotter M., Buxton B.. Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis. Comput. Chem. 2001, 26 (1), 5–14.
59. Warmuth M. K., Liao J., Ratsch G.. Active Learning with Support Vector Machines in the Drug Discovery Process. J. Chem. Inf. Comput. Sci. 2003, 43 (2), 667–673.
60. Finne P., Finne R., Auvinen A.. Predicting the Outcome of Prostate Biopsy in Screen-Positive Men by a Multilayer Perceptron Network. Urology 2000, 56 (3), 418–422.
61. Matsui Y., Egawa S., Tsukayama C.. Artificial Neural Network Analysis for Predicting Pathological Stage of Clinically Localized Prostate Cancer in the Japanese Population. Jpn. J. Clin. Oncol. 2002, 32 (12), 530–535.
62. Tan A. C., Gilbert D., Ensemble Machine Learning on Gene Expression Data for Cancer Classification. Appl. Bioinformatics 2003, 2 (3 Suppl.), S75–S83.
63. Menden M. P., Iorio F., Garnett M.. Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties. PLoS One 2013, 8 (4), e61318.
64. Yang W., Soares J., Greninger P.. Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells. Nucleic Acids Res. 2013, 41 (Database issue), D955–D961.
65. Altmann A., Beerenwinkel N., Sing T.. Improved Prediction of Response to Antiretroviral Combination Therapy Using the Genetic Barrier to Drug Resistance. Antivir. Ther. 2007, 12 (2), 169–178.
66. Bickel S., Bogojeska J., Lengauer T.. In Multi-Task Learning for HIV Therapy Screening, Proceedings of the 25th International Conference on Machine Learning, Helsinki, Finland, 2008; pp 56–63.
67. Zazzi M., Incardona F., Rosen-Zvi M.. Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project. Intervirology 2012, 55 (2), 123–127.
68. Rosen-Zvi M., Altmann A., Prosperi M.. Selecting Anti-HIV Therapies Based on a Variety of Genomic and Clinical Factors. Bioinformatics 2008, 24 (13), i399–i406.
69. Cenci M., Nagar C., Vecchione A., PAPNET-Assisted Primary Screening of Conventional Cervical Smears. Anticancer Res. 2000, 20 (5C), 3887–3889.
70. Snow P. B., Smith D. S., Catalona W. J., Artificial Neural Networks in the Diagnosis and Prognosis of Prostate Cancer: A Pilot Study. J. Urol. 1994, 152 (5 Pt 2), 1923–1926.
71. Berenbaum M. C., Direct Search Methods in the Optimisation of Cancer Chemotherapy Regimens. Br. J. Cancer 1990, 61 (1), 101–109.
72. Nelder J. A., Mead R., A Simplex-Method for Function Minimization. Comput. J. 1965, 7 (4), 308–313.
73. Box M. J., A New Method of Constrained Optimization and a Comparison with Other Methods. Comput. J. 1965, 8 (1), 42–52.
74. Curatolo M., Schnider T. W., Petersen-Felix S.. A Direct Search Procedure to Optimize Combinations of Epidural Bupivacaine, Fentanyl, and Clonidine for Postoperative Analgesia. Anesthesiology 2000, 92 (2), 325–337.
75. Curatolo M., Sveticic G. Drug Combinations in Pain Treatment: A Review of the Published Evidence and a Method for Finding the Optimal Combination. Best Pract. Res. Clin. Anaesthesiol. 2002, 16 (4), 507–519.
76. Sveticic G., Gentilini A., Eichenberger U.. Combinations of Morphine with Ketamine for Patient-Controlled Analgesia: A New Optimization Method. Anesthesiology 2003, 98 (5), 1195–1205.
77. Calzolari D., Bruschi S., Coquin L.. Search Algorithms as a Framework for the Optimization of Drug Combinations. PLoS Comput. Biol. 2008, 4 (12), e1000249.
78. Park M., Nassar M., Vikalo H., Bayesian Active Learning for Drug Combinations. IEEE Trans. Biomed. Eng. 2013, 60 (11), 3248–3255.
79. Wong P. K., Yu F., Shahangian A.. Closed-Loop Control of Cellular Functions Using Combinatory Drugs Guided by a Stochastic Search Algorithm. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (13), 5105–5110.
80. Yoon B. J., Enhanced Stochastic Optimization Algorithm for Finding Effective Multi-Target Therapeutics. BMC Bioinformatics 2011, 12 (Suppl. 1), S18.
81. Tsutsui H., Valamehr B., Hindoyan A.. An Optimized Small Molecule Inhibitor Cocktail Supports Long-Term Maintenance of Human Embryonic Stem Cells. Nat. Commun. 2011, 2, 167.
82. Ding X., Sanchez D. J., Shahangian A.. Cascade Search for HSV-1 Combinatorial Drugs with High Antiviral Efficacy and Low Toxicity. Int. J. Nanomed. 2012, 7, 2281–2292.
83. Wei F., Bai B., Ho C. M., Rapidly Optimizing an Aptamer Based BoNT Sensor by Feedback System Control (FSC) Scheme. Biosens. Bioelectron. 2011, 30 (1), 174–179.
84. Weiss A., Ding X., van Beijnum J. R.. Rapid Optimization of Drug Combinations for the Optimal Angiostatic Treatment of Cancer. Angiogenesis 2015, 18 (3), 233–244.
85. Berndsen R. H., Weiss A., Wong T. J.. Synergy between Ruthenium(II)-Arene Complex [Ru(ɳ6-p-Cymene)Cl2(pta)] (RAPTA-C) and the Epidermal Growth Factor Receptor Inhibitor Erlotinib Results in Angiostatic and Antitumor Activity. Sci. Rep. 2016, in press.
86. Tse S. M., Liang Y., Leung K. S.. A Memetic Algorithm for Multiple-Drug Cancer Chemotherapy Schedule Optimization. IEEE Trans. Syst. Man Cybern. B 2007, 37 (1), 84–91.
87. Zinner R. G., Barrett B. L., Popova E.. Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells. Mol. Cancer Ther. 2009, 8 (3), 521–532.
88. Park M., Nassar M., Evans B.. Adaptive Experimental Design for Drug Combinations. IEEE Stat. Signal Processing Workshop 2012, 712–715.
89. Chen D., Liu X., Yang Y.. Systematic Synergy Modeling: Understanding Drug Synergy from a Systems Biology Perspective. BMC Syst. Biol. 2015, 9, 56.
90. Iadevaia S., Lu Y., Morales F. C.. Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis. Cancer Res. 2010, 70 (17), 6704–6714.
91. Zhang Y., Smolen P., Baxter D. A.. Computational Analyses of Synergism in Small Molecular Network Motifs. PLoS Comput. Biol. 2014, 10 (3), e1003524.
92. Araujo R. P., Petricoin E. F., Liotta L. A., A Mathematical Model of Combination Therapy Using the EGFR Signaling Network. Bio Syst. 2005, 80 (1), 57–69.
93. Facchetti G., Zampieri M., Altafini C., Predicting and Characterizing Selective Multiple Drug Treatments for Metabolic Diseases and Cancer. BMC Syst. Biol. 2012, 6.
94. Orth J. D., Thiele I., Palsson B. O., What Is Flux Balance Analysis? Nat. Biotechnol. 2010, 28 (3), 245–248.
95. Ryall K. A., Tan A. C., Systems Biology Approaches for Advancing the Discovery of Effective Drug Combinations. J. Cheminformatics 2015, 7, 7.
96. Kraeutler M. J., Soltis A. R., Saucerman J. J., Modeling Cardiac Beta-Adrenergic Signaling with Normalized-Hill Differential Equations: Comparison with a Biochemical Model. BMC Syst. Biol. 2010, 4, 157.
97. Albert I., Thakar J., Li S.. Boolean Network Simulations for Life Scientists. Source Code Biol. Med. 2008, 3, 16.
98. Glass L., Kauffman S. A., The Logical Analysis of Continuous, Non-Linear Biochemical Control Networks. J. Theor. Biol. 1973, 39 (1), 103–129.
99. Wittmann D. M., Krumsiek J., Saez-Rodriguez J.. Transforming Boolean Models to Continuous Models: Methodology and Application to T-Cell Receptor Signaling. BMC Syst. Biol. 2009, 3, 98.
100. Aldridge B. B., Saez-Rodriguez J., Muhlich J. L.. Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling. PLoS Comput. Biol. 2009, 5 (4), e1000340.
101. Ryall K. A., Bezzerides V. J., Rosenzweig A.. Phenotypic Screen Quantifying Differential Regulation of Cardiac Myocyte Hypertrophy Identifies CITED4 Regulation of Myocyte Elongation. J. Mol. Cell. Cardiol. 2014, 72, 74–84.
102. Molinelli E. J., Korkut A., Wang W.. Biology: Inferring Signaling Networks in Cellular Systems. PLoS Comput. Biol. 2013, 9 (12), e1003290.
103. Nelander S., Wang W., Nilsson B.. Models from Experiments: Combinatorial Drug Perturbations of Cancer Cells. Mol. Syst. Biol. 2008, 4, 216.
104. Korkut A., Wang W., Demir E.. Perturbation Biology Nominates Upstream-Downstream Drug Combinations in RAF Inhibitor Resistant Melanoma Cells. eLife 2015, 4.
105. Tyner J. W., Yang W. F., Bankhead A., 3rd. Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Res. 2013, 73 (1), 285–296.
106. Pal R., Berlow N. A Kinase Inhibition Map Approach for Tumor Sensitivity Prediction and Combination Therapy Design for Targeted Drugs. Pac. Symp. Biocomput. 2012, 351–362.
107. Tang J., Karhinen L., Xu T.. Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. PLoS Comput. Biol. 2013, 9 (9), e1003226.
108. Gujral T. S., Peshkin L., Kirschner M. W., Exploiting Polypharmacology for Drug Target Deconvolution. Proc. Natl. Acad. Sci. U.S.A. 2014, 111 (13), 5048–5053.
109. Zhao X. M., Iskar M., Zeller G.. Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data. PLoS Comput. Biol. 2011, 7 (12), e1002323.
110. Xu K. J., Song J., Zhao X. M., The Drug Cocktail Network. BMC Syst. Biol. 2012, 6 (Suppl. 1), S5.
111. Wang Y. Y., Xu K. J., Song J.. Exploring Drug Combinations in Genetic Interaction Network. BMC Bio-informatics 2012, 13 (Suppl. 7), S7.
112. Montgomery D. C., Peck E. A., Vining G. G., Introduction to Linear Regression Analysis; Wiley: Hoboken, NJ, 2012; 5th ed., p xvi.
113. Jaynes J., Ding X., Xu H.. Application of Fractional Factorial Designs to Study Drug Combinations. Stat. Med. 2013, 32 (2), 307–318.
114. Weiss A., Bonvin D., Berndsen B.. Angiostatic Treatment Prior to Chemo- or Photodynamic Therapy Improves Anti-Tumor Efficacy. Sci. Rep. 2015, 5, 8990.
115. Al-Shyoukh I., Yu F., Feng J.. Systematic Quantitative Characterization of Cellular Responses Induced by Multiple Signals. BMC Syst. Biol. 2011, 5, 88.
116. Yu F., Al-Shyoukh I., Feng J.. Control of Kaposi’s Sarcoma-Associated Herpesvirus Reactivation Induced by Multiple Signals. PLoS One 2011, 6 (6), e20998.
117. Ding X., Liu W., Weiss A.. Discovery of a Low Order Drug-Cell Response Surface for Applications in Personalized Medicine. Phys. Biol. 2014, 11 (6), 065003.
118. Box G. E. P., Robustness in the Strategy of Scientific Model Building. In Robustness in Statistics; Launer R. L., Wilkinson G. N., Eds.; Elsevier: Amsterdam, 1979; pp 201–236.
119. Gomeni R., Bressolle F., Fava M., Response Surface Analysis and Non-Linear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended Release and Long-Acting-Injectable Paliperidone. J. Clin. Pharmacol. 2016, 38 (10S), e4.
120. Lisboa P. J., Taktak A. F., The Use of Artificial Neural Networks in Decision Support in Cancer: A Systematic Review. Neural Netw. 2006, 19 (4), 408–415.